MX2012009529A - Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. - Google Patents

Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno.

Info

Publication number
MX2012009529A
MX2012009529A MX2012009529A MX2012009529A MX2012009529A MX 2012009529 A MX2012009529 A MX 2012009529A MX 2012009529 A MX2012009529 A MX 2012009529A MX 2012009529 A MX2012009529 A MX 2012009529A MX 2012009529 A MX2012009529 A MX 2012009529A
Authority
MX
Mexico
Prior art keywords
arthritis
disease
cartilage
chronic
injury
Prior art date
Application number
MX2012009529A
Other languages
English (en)
Inventor
Guozhang Xu
Bao-Ping Zhao
Michael Gaul
Gilles Bignan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2012009529A publication Critical patent/MX2012009529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de formula (I) métodos para preparar estos compuestos, composiciones, intermediarios y derivados de los mismos y para tratar una condición que incluye pero no se limita a espondilitis anquilosante, arteroesclerosis, artritis (tal como artritis reumatoide, artritis infecciosa, artritis infantil, artritis soriática, artritis reactiva), enfermedades relacionadas con los huesos (incluyendo aquellas relacionadas con la formación de los huesos), cáncer de mama (incluyendo aquellos insensibles a la terapia antiestrógenos), trastornos cardiovasculares, enfermedad relacionada con los cartílagos (tal como lesión/pérdida de cartílagos, degeneración de cartílagos, y aquellas relacionadas con la formación de los cartílagos), condrodisplasia, condrosarcoma, lesión crónica de la espalda, bronquitis crónica, enfermedad inflamatoria crónica de las vías respiratorias, enfermedad pulmonar obstructiva crónica, diabetes, trastornos de la homeostasis de energía, gota, pseudogota, trastornos de lípidos, síndrome metabólico, mieloma múltiple, obesidad, osteoartritis, osteogénesis imperfecta, metástasis ósea osteolítica, osteomalacia, osteoporosis, enfermedad de Paget, enfermedad periodontal, polimialgia reumática, síndrome de Reiter, lesion por tension repetitiva, hiperglucemia, nivel elevado de glucosa en la sangre y resistencia a la insulina.
MX2012009529A 2010-02-17 2011-02-16 Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. MX2012009529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30518110P 2010-02-17 2010-02-17
PCT/US2011/025004 WO2011103134A1 (en) 2010-02-17 2011-02-16 Aminothiazolones as estrogen related receptor-alpha modulators

Publications (1)

Publication Number Publication Date
MX2012009529A true MX2012009529A (es) 2013-01-14

Family

ID=43927926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009529A MX2012009529A (es) 2010-02-17 2011-02-16 Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno.

Country Status (13)

Country Link
US (1) US8445690B2 (es)
EP (1) EP2536717B1 (es)
JP (1) JP2013519730A (es)
KR (1) KR20130001242A (es)
CN (1) CN102834392A (es)
AR (1) AR080207A1 (es)
AU (1) AU2011218190A1 (es)
CA (1) CA2789757A1 (es)
MX (1) MX2012009529A (es)
RU (1) RU2012139463A (es)
TW (1) TW201144303A (es)
UY (1) UY33231A (es)
WO (1) WO2011103134A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013051632A1 (ja) * 2011-10-04 2013-04-11 武田薬品工業株式会社 含窒素縮合複素環化合物
WO2013146435A1 (ja) 2012-03-26 2013-10-03 日本ケミファ株式会社 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤
CN104119285B (zh) * 2013-04-28 2016-06-29 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
KR20220000993A (ko) 2013-09-25 2022-01-04 닛뽕 케미파 가부시키가이샤 골·연부에 발생하는 거세포성 종양, 연골육종 또는 골육종의 예방, 치료 또는 전이 예방을 위한 약제, 동맥색전술용 국소 주입제 및 인공골
ES2764660T3 (es) 2014-12-16 2020-06-04 Axovant Sciences Gmbh Compuestos de amida de quinuclidina sustituida geminal como agonistas de receptores alfa-7 nicotínicos de acetilcolina
CN104610157A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类环丙基酰肼和卤代苯类结构的gpr119激动剂及其用途
AU2016274694A1 (en) 2015-06-10 2018-01-18 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217983A (en) * 1992-03-27 1993-06-08 Du Pont Merck Pharmaceutical Company (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
WO1997040017A2 (en) * 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
CN1246868A (zh) 1996-12-17 2000-03-08 扇形支撑剑桥有限公司 黑皮素
EP1781271A1 (en) * 2004-07-14 2007-05-09 Janssen Pharmaceutica N.V. Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
US8148361B2 (en) * 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
DK2132188T3 (da) * 2007-03-07 2012-02-27 Janssen Pharmaceutica Nv Substituerede phenoxy-N-alkylerede thiazolidindioner som østrogenrelaterede receptor-alfa-modulatorer
HUE025471T2 (hu) * 2008-04-16 2016-03-29 Karobio Ab Új ösztrogén receptor ligandumok

Also Published As

Publication number Publication date
US20110200587A1 (en) 2011-08-18
US8445690B2 (en) 2013-05-21
KR20130001242A (ko) 2013-01-03
AR080207A1 (es) 2012-03-21
UY33231A (es) 2011-08-31
CN102834392A (zh) 2012-12-19
WO2011103134A1 (en) 2011-08-25
EP2536717A1 (en) 2012-12-26
JP2013519730A (ja) 2013-05-30
TW201144303A (en) 2011-12-16
EP2536717B1 (en) 2014-06-04
AU2011218190A1 (en) 2012-09-06
CA2789757A1 (en) 2011-08-25
RU2012139463A (ru) 2014-03-27

Similar Documents

Publication Publication Date Title
UA98484C2 (ru) ЗАМЕЩЕННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ КАК МОДУЛЯТОРЫ α-РЕЦЕПТОРА ЭСТРОГЕНА
MX2009009519A (es) Fenoxitiazolidinodionas n-alquiladas sustituidas como moduladores de receptor- alfa relacionados con estrogeno.
UA98485C2 (ru) ЗАМЕЩЕННЫЕ ФЕНОКСИТИАЗОЛИДИНДИОНЫ КАК МОДУЛЯТОРЫ α-РЕЦЕПТОРА ЭСТРОГЕНА
MX2012009529A (es) Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno.
MX2012009528A (es) Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno.
AR081221A1 (es) Anticuerpos anti gdf8 humano
JP2010520306A5 (es)
TN2010000125A1 (en) Substituted biphenyl gpr40 modulators
JP2010520307A5 (es)
JP2012506473A5 (es)
JP2009513806A5 (es)
JP2011516700A5 (es)
MY156976A (en) Adhesive and sealants containing cyclohexane dicarboxylic acid esters
MX2013011257A (es) Proceso para la preparacion de dronedarona por n-butilacion.
CA2715113A1 (en) 11 beta-hydroxysteroid dehydrogenase inhibitors
CY1124919T1 (el) Κρυσταλλικη μορφη τριυδριτη toy (3s,3s') 4,4'-δισουλφανοδιυλοδις(3-αμινοβουτανο 1-σουλφονικου οξεος)
UA97975C2 (ru) ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛОВАННЫЕ ТИАЗОЛИДИНДИОНЫ КАК МОДУЛЯТОРЫ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α
Nguyen et al. Synthesis of the bio-based alternative to Bis-GMA and its application to photo-polymerizable adhesives
JP2017507138A5 (es)
MY160230A (en) Thermoplastic stiffening materials
JP2020502084A5 (es)
JP2012233153A5 (es)
JP2017505765A5 (es)
CN107011212A (zh) 一种氰乙酸仲辛酯的制备方法
JP2016023176A (ja) 化合物及びその製造方法

Legal Events

Date Code Title Description
FA Abandonment or withdrawal